Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609535 | 0.89 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL11871555 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL11871558 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| Cicrotoic Acid SCHEMBL2773334 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL28205563 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| Cicrotoic Acid SCHEMBL2773332 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| Cicrotoic Acid SCHEMBL1642993 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL8038776 | 0.77 | CES2 (0.42) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL8034602 | 0.77 | CES2 (0.42) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL8034597 | 0.77 | CES2 (0.42) | CES2CES1HDAC8HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3864966-A1 | ORAL COMPOSITIONS COMPRISING ALLULOSE CRYSTALS | Savanna Ingredients GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-9545413-B2 | Methods of forming ciclopirox or derivatives thereof in a subject by administration of prodrug | UNIVERSITY OF KANSAS (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160095870-A1 | METHODS OF FORMING CYCLOPIROX OR DERIVATIVES THEREOF IN A SUBJECT BY ADMINISTRATION OF PRODRUG | UNIV KANSAS (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095870-A1 | METHODS OF FORMING CYCLOPIROX OR DERIVATIVES THEREOF IN A SUBJECT BY ADMINISTRATION OF PRODRUG | MCL1, MALT1, DPM1 | CES2 736/4885CES1 574/4885HDAC8 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.